CoChat

Therapeutic potential of targeting micro RNA ‐10b in established intracranial glioblastoma: first steps toward the clinic

Open access
Teplyuk, Nadiya M, Uhlmann, Erik J, Gabriely, Galina, Volfovsky, Natalia, Wang, Yang, Teng, Jian, Karmali, Priya, Marcusson, Eric, Peter, Merlene, Mohan, Athul, Kraytsberg, Yevgenya, Cialic, Ron, Chiocca, E Antonio, Godlewski, Jakub, Tannous, Bakhos, Krichevsky, Anna M · 2016 · EMBO Molecular Medicine
Cited by 138

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

MicroRNA-10b (miR-10b) is a unique oncogenic miRNA that is highly expressed in all GBM subtypes, while absent in normal neuroglial cells of the brain. miR-10b inhibition strongly impairs proliferation and survival of cultured glioma cells, including glioma-initiating stem-like cells (GSC). Although several miR-10b targets have been identified previously, the common mechanism conferring the miR-10b-sustained viability of GSC is unknown. Here, we demonstrate that in heterogeneous GSC, miR-10b regulates cell cycle and alternative splicing, often through the non-canonical targeting via 5'UTRs of its target genes, including MBNL1-3, SART3, and RSRC1. We have further assessed the inhibition of miR-10b in intracranial human GSC-derived xenograft and murine GL261 allograft models in athymic and immunocompetent mice. Three delivery routes for the miR-10b antisense oligonucleotide inhibitors (ASO), direct intratumoral injections, continuous osmotic delivery, and systemic intravenous injections, have been explored. In all cases, the treatment with miR-10b ASO led to targets' derepression, and attenuated growth and progression of established intracranial GBM. No significant systemic toxicity was observed upon ASO administration by local or systemic routes. Our results indicate that miR-10b is a promising candidate for the development of targeted therapies against all GBM subtypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201505495

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 138

Metadata

Authors
Teplyuk, N. M., Uhlmann, E. J., Gabriely, G., Volfovsky, N., Wang, Y., Teng, J., Karmali, P., Marcusson, E., Peter, M., Mohan, A., Kraytsberg, Y., Cialic, R., Chiocca, E. A., Godlewski, J., Tannous, B., & Krichevsky, A. M.
Venue
EMBO Molecular Medicine
Published
2016-02-10
Volume
8
Issue
3
Pages
268-287
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2262087088
Cited by
138
References
16
FWCI
6.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic potential of targeting micro RNA ‐10b in established intracranial glioblastoma: first steps toward the clinic. https://app.cochat.ai/papers/10.15252/emmm.201505495
The paper
Teplyuk, N. M., Uhlmann, E. J., Gabriely, G., Volfovsky, N., Wang, Y., Teng, J., Karmali, P., Marcusson, E., Peter, M., Mohan, A., Kraytsberg, Y., Cialic, R., Chiocca, E. A., Godlewski, J., Tannous, B., & Krichevsky, A. M. (2016). Therapeutic potential of targeting micro RNA ‐10b in established intracranial glioblastoma: first steps toward the clinic. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201505495

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.